Zofran Lawsuit Frequently Asked Questions Answered In Video From ZofranLegal.com

April 05, 2016 – – ZofranLegal.com reports on a series of video releases by Monheit Law attorneys. One of the videos in the series was created to assist those who may be contemplating filing a lawsuit and who have questions regarding the process. Hundreds of parents from across the United States have now stepped forward to file lawsuits against pharmaceutical giant GlaxoSmithKline in reference to the anti-nausea drug they market, Zofran. This can be a confusing but very rewarding process and the attorneys of Monheit Law are working to simplify it for deserving individuals, who may be entitled to significant compensation through legal action.

This particular video release focuses on explaining the two most frequently asked questions that those looking into filing a lawsuit ask: how much does the legal process cost and how does it work. The attorneys of Monheit Law sponsor online resource website ZofranLegal.com, which provides important information to the public concerning the anti-nausea drug Zofran and its potential links to the development of birth defects in unborn babies.

Zofran birth defect lawsuits filed by parents from across the country now number in the hundreds, and were transferred and consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2657 in a single Court in Boston, Massachusetts. Involved plaintiffs similarly allege that when Zofran is exposed to fetuses growing in the womb through their mothers, it can place these babies at increased risk for the development of serious and sometimes fatal birth defects. Plaintiffs most commonly connect fetal Zofran exposure to the potential development of cleft lip and palate, atrial and ventricular septal defect, transposition of the greater vessels, tetralogy of fallot, kidney defects, clubfoot, and respiratory distress.

Nationally, pregnant women are given prescriptions of Zofran to combat nausea and vomiting episodes frequently associated with morning sickness. Morning sickness is most commonly experienced during a woman’s first trimester of pregnancy. Interestingly enough, however, this is also a time when the fetus experiences rapid cell growth, and when it forms much of its initial heart, mouth, and limb tissue development.

A point of contention among Zofran lawsuit plaintiffs is that the drug was never FDA approved to treat pregnant women in the first place, or tested for safety on these women and their unborn children. Instead, the agency specifically approved the drug to treat patients who had undergone radiation, chemotherapy, or anesthesia, all of which can induce nausea and vomiting. Despite this very specific approval, however, corporate giant GlaxoSmithKline began to market the drug as a safe and effective treatment for morning sickness to the general public and OB/Gyn offices across the nation. This “off-label” marketing led to many “off-label” prescriptions, and, according to current lawsuit plaintiffs, to the development of many birth defects in children.

Michael Monheit, Esq. of Monheit Law is now working to help other women who used Zofran while pregnant and who later gave birth to children with defects. He wants to ensure that affected mothers given the critical opportunity to fully explore their legal rights in the matter. It is their hope that this informational video series will help to accomplish this. Affected mothers, children, and family members may be entitled to significant compensation attained through legal action. At this time, Monheit Law is also offering free legal consultations to qualified parties.

To request further information, or to ask questions, contact Michael Monheit, Esq. by calling 877-620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60009093